Latest news
Old molecules show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2 continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, researchers have identified several promising molecules that could lead to new medications capable of combating these resistant variants.
New study reveals how natural humic substances reshape soil carbon cycling and boost antibiotic resistance
Researchers have uncovered surprising links between natural humification processes in soil, carbon metabolism, and the spread of antibiotic resistance. Subtle shifts in the composition of humic substances can reshape microbial metabolism and alter the abundance of antibiotic resistance genes.
How can nursing homes protect more patients from infections?
New US national guidance calls for full-time infection prevention staff; more training, support and vaccination for all staff; and partnerships with hospitals and public health agencies.
What are the new guidelines for infant hepatitis B vaccination?
Public health expert and infectious disease physician Janet A. Jokela comments after the Advisory Committee on Immunization Practices of the CDC voted to discontinue its decades-long recommendation for universal vaccination against hepatitis B beginning at birth.
AFYREN and ESSE Skincare begin partnership to offer 100% natural cosmetic solutions with enhanced skincare performance
AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology, and South Africa-based Esse Skincare, a leader in microbiome skincare science, are partnering to introduce the world’s first bio-based propionic acid for the skincare industry.
Nature’s 10: Ten people who shaped science in 2025
Microbiologists and scientists tackling infectious diseases are among Nature’s annual list of ten people at the heart of some of the biggest science stories of 2025.
Old molecules show promise for fighting resistant strains of COVID-19 virus
SARS‑CoV‑2 continues to mutate, with some newer strains becoming less responsive to current antiviral treatments like Paxlovid. Now, researchers have identified several promising molecules that could lead to new medications capable of combating these resistant variants.
New study reveals how natural humic substances reshape soil carbon cycling and boost antibiotic resistance
Researchers have uncovered surprising links between natural humification processes in soil, carbon metabolism, and the spread of antibiotic resistance. Subtle shifts in the composition of humic substances can reshape microbial metabolism and alter the abundance of antibiotic resistance genes.
New study reveals that parasite-produced dopamine can alter host behaviour
A new study has shed light on how Toxoplasma gondii, the causative agent of toxoplasmosis, can alter host behaviour. The research findings show that such behavioural changes are achieved, at least in part, through dopamine manipulation caused by dopamine produced by the parasite itself.
AFYREN and ESSE Skincare begin partnership to offer 100% natural cosmetic solutions with enhanced skincare performance
AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology, and South Africa-based Esse Skincare, a leader in microbiome skincare science, are partnering to introduce the world’s first bio-based propionic acid for the skincare industry.
Apriori Bio and A*STAR Infectious Diseases Labs Announce strategic partnership to advance next generation influenza vaccines
Apriori Bio and the Agency for Science, Technology and Research Infectious Diseases Labs (A*STAR IDL) announced a strategic research partnership to co-develop and evaluate next generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza.
Typhoid conjugate vaccine demonstrates strong safety and immunogenicity: Results from Phase 3 study
PATH and EuBiologics Co., LTD have announced Phase 3 results from a clinical trial of a typhoid conjugate vaccine (TCV), EuTYPH-C Inj.® Multi-dose. EuTYPH-C Inj.®
Microenvironment-feedback hydrogel enables precise staged repair of infected wounds
A research team has developed a hydrogel that can sense changes in wound pH and automatically switches its therapeutic behavior from fighting infection to promoting tissue repair.
Researchers use ‘brain-on-a-chip’ to revolutionize fight against deadly encephalitis viruses
A transparent chip no larger than a stick of gum is helping scientists transform the way researchers study the human brain and develop treatments for some of the world’s deadliest viruses.
New test distinguishes vaccine-induced false positives from active HIV infection
A new device correctly identified those with active HIV-1 infection 95% of the time and those without active infection but with vaccine-induced molecules that could trigger a false positive, 98% of the time.
How can nursing homes protect more patients from infections?
New US national guidance calls for full-time infection prevention staff; more training, support and vaccination for all staff; and partnerships with hospitals and public health agencies.
What are the new guidelines for infant hepatitis B vaccination?
Public health expert and infectious disease physician Janet A. Jokela comments after the Advisory Committee on Immunization Practices of the CDC voted to discontinue its decades-long recommendation for universal vaccination against hepatitis B beginning at birth.
Nature’s 10: Ten people who shaped science in 2025
Microbiologists and scientists tackling infectious diseases are among Nature’s annual list of ten people at the heart of some of the biggest science stories of 2025.